#### Catalog # LY1-H5255



#### Synonym

LYPD1,Ly6/PLAUR domain-containing protein 1,FLJ41033,LY6/PLAUR domain containing 1,LYPDC1,PHTS,Putative HeLa tumor suppressor

#### Source

Human LYPD1 Protein, Llama IgG2b Fc Tag(LY1-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 21 - Gly 115 (Accession # <u>Q8N2G4-1</u>).

Predicted N-terminus: Leu 21

### **Molecular Characterization**

```
LYPD1(Leu 21 - Gly 115)
                   LlamaFc(Glu 1 - Ser 243)
Q8N2G4-1
                         AAX73259.1
```

This protein carries a llama IgG2b Fc tag at the C-terminus

The protein has a calculated MW of 38.2 kDa. The protein migrates as 47-52 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

#### Endotoxin

Less than 0.01 EU per  $\mu$ g by the LAL method.

## **Purity**

>90% as determined by SDS-PAGE.

#### **Formulation**

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

#### Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

## **SDS-PAGE**



Human LYPD1 Protein, Llama IgG2b Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

### **Bioactivity-ELISA**

#### 戻LYPD1 ELISA

Immobilized Human LYPD1 Protein, Llama IgG2b Fc Tag (Cat. No. LY1-H5255) at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Anti-LYPD1 antibody with a linear range of 0.02-0.625  $\mu$ g/mL (QC tested).

>>> www.acrobiosystems.com

8/14/2023

Catalog # LY1-H5255

# **ACTO**

## Background

Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety.

## **Clinical and Translational Updates**

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.



8/14/2023